Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on May 14, 2021 12:48pm
166 Views
Post# 33204012

News from Taimed

News from Taimed
Zhongyu (4147-TW) announced today (14) that the European Union’s medical certification authority EMA has notified the foundry of Trogarzo, a new AIDS drug, to South Korea’s Samsung Biologics (SBL), and will conduct an inspection in two weeks. If the inspection is approved, the production capacity will be increased. Enlarged, the overall gross profit margin is also expected to grow simultaneously.
 
The new AIDS drug Trogarzo developed by Zhongyu has been co-founded by South Korea’s Samsung Biologics (SBL) in 2019. It is currently produced in a 2000L bioreactor. The two parties have recently expanded the production of Trogarzo and changed its production capacity to the 15000L bioreactor at the Samsung plant in Incheon. At present, all batches of process performance verification (PPQ) have been completed and entered the stability test stage.
 
Zhongyu said that the European Union's medical certification authority EMA will go to the plant for inspection in two weeks. If the inspection is passed, the Trogarzo bioreactor will be expanded from 2000L to 15000L, which will help increase the gross profit margin.
 
In terms of Trogarzo sales, Zhongyu pointed out that with the gradual control of the new crown epidemic in the United States, the inventory adjustment of the US marketing partner Theratechnologies has also come to an end. The second quarter began to restart the sales, and the expected revenue performance is expected to recover at the same time. In addition, the Trogarzo intravenous bolus dosage form has the opportunity to be launched in the United States at the end of this year and the first quarter of next year.
 
In terms of the European market layout, Zhongyu said that it has completed the price setting of health insurance drugs with the German competent authority. In addition, if the epidemic in Europe gradually slows down in the future, it will expand the market to France.

https://hk.news.yahoo.com/--031410627.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAABTA7m12ntY8DjUUTp6u4dhobjTdrIj4JFx4r76FaEMMfUdoH9TX0FLjE3R1rCUyQSryugLbTL7HMzSwe3BofFx18wslCn9vr53fyLAzAA23C4X4iG7qk26BR7Y3Q07wkCT92m0nE2KCs119wkm6S751er6kodD9n3kJ1QClW2Xb

 
<< Previous
Bullboard Posts
Next >>